Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay


Creative Commons License

Coban A. Y., BIRINCI A., EKINCI B. T., DURUPINAR B.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, cilt.24, sa.3, ss.304-306, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 3
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.ijantimicag.2004.02.027
  • Dergi Adı: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.304-306
  • Anahtar Kelimeler: Mycobacterium tuberculosis, nitrate reductase assay, susceptibility testing, GROWTH INDICATOR TUBE, COLORIMETRIC METHOD, RIFAMPIN, SYSTEM
  • Akdeniz Üniversitesi Adresli: Hayır

Özet

The nitrate reductase assay (NRA) was evaluated for susceptibility testing of Mycobacterium tuberculosis using 80 clinical isolates of M. tuberculosis and H37Rv as a control strain. All isolates were tested by the proportion method and the NRA for isoniazid (INH), rifampicin (RIF), streptomycin (STR) and ethambutol (ETM). The proportion method was carried out according to NCCLS on Lowenstein-Jensen (U) medium and the NRA on U medium containing 1000 mug/ml potassium nitrate (KNO3). After incubation for 7, 10, 14 and 21 days, Griess reagent was added to each LJ medium and nitrate reduction was determined by a colour change. Comparing the NRA with the proportion method, sensitivities were 100, 100, 82.1 and 92.2% for INH, RIF, STR and ETM, respectively. Specificities were 100, 100, 92.3 and 100% for INH, RIF, STR and ETM, respectively. The results of 2, 22 and 56 isolates were obtained after 7, 10 and 14 days, respectively. The proportion method result were read at 21-28 days. The NRA is rapid, inexpensive and easy to perform. Our results indicated that the NRA is suitable for the early determination of INH and RIF resistance in countries where sophisticated procedures are not always available. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.